Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03183973
Other study ID # SCARM-Sternum repair
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 5, 2020
Est. completion date December 25, 2020

Study information

Verified date June 2020
Source SCARM Institute, Tabriz, Iran
Contact Ahmad Reza Jodati, CTS
Phone 0413 33349525
Email Jodatia@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sternal wound and there complication such as infection, Bruising and scar formation are known as major complication cardiac surgery with a high mortality rate up to 50%. Several approaches have been proposed for treatment of chronic sternal wounds in these patients. however, Underlying confounding factors such as old ages,diabetes mellitus, systemic hypoxia, atherosclerosis and malnutrition have main role against wound repairing. In this study investigators aimed to treatment of patients with open heart surgery and need to strict monitoring of sternal wound repair by Platelet Rich Fibrin.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 25, 2020
Est. primary completion date October 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - The patient has been diagnosed with an acute STEMI or NSTEMI (confirmed by segment elevation (ST) changes on serial ECG, elevated troponin, coronary artery stenosis or occlusion identified by angiography, and a wall motion abnormality identified by angiography or echocardiography) - The patient is scheduled to undergo coronary artery bypass surgery. - The patient does not possess any contraindication for cardiovascular magnetic resonance (CMR). - The patient is capable of giving informed consent. - The patient is geographically accessible and willing to return for all follow-up investigations and clinical visits associated with study. Exclusion Criteria: - The patient is over the age of 65 years. - The patient has previous myocardial infarction (MI) (other than the qualifying event) and/or has scar or non-viable myocardium identified by CMR in any other left ventricular (LV) territory. - The patient is undergoing other cardiac surgery (i.e. concurrent cardiac valve, or aortic surgery). - The patient requires emergency surgery (i.e. operative intervention (CABG or ventricular assist device) within 24-hrs of assessment). - The patient has undergone previous cardiac surgery. - The patient's postsurgical life expectancy is less than 45 days, in the investigator's opinion. - The patient is of excessively poor baseline health, health-related quality of life, or physical functioning that would preclude a reasonable expected post-operative recovery. - The patient has received radiotherapy to the chest wall, is receiving immunosuppressive therapy, or is in any way immunocompromised.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PRF
patients who will receive PRF suspension
placebo group
patients who will receive Placebo

Locations

Country Name City State
Iran, Islamic Republic of SCARM Tabriz East Azarbyjan

Sponsors (1)

Lead Sponsor Collaborator
SCARM Institute, Tabriz, Iran

Country where clinical trial is conducted

Iran, Islamic Republic of, 

References & Publications (3)

Cotogni P, Barbero C, Rinaldi M. Deep sternal wound infection after cardiac surgery: Evidences and controversies. World J Crit Care Med. 2015 Nov 4;4(4):265-73. doi: 10.5492/wjccm.v4.i4.265. eCollection 2015 Nov 4. — View Citation

Serraino GF, Dominijanni A, Jiritano F, Rossi M, Cuda A, Caroleo S, Brescia A, Renzulli A. Platelet-rich plasma inside the sternotomy wound reduces the incidence of sternal wound infections. Int Wound J. 2015 Jun;12(3):260-4. doi: 10.1111/iwj.12087. Epub — View Citation

Tashnizi MA, Alamdari DH, Khayami ME, Rahimi HR, Moeinipour A, Amouzeshi A, Seifalian AM. Treatment of non-healing sternum wound after open-heart surgery with allogenic platelet-rich plasma and fibrin glue-preliminary outcomes. Indian J Plast Surg. 2013 S — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Scar formation Appearance of operative scar diagnose by cardiothoracic surgeon post operative- until release from hospitalization up to 1 month
Primary Wound Infection wound infection incidence diagnose by cardiothoracic surgeon post operative- until release from hospitalization up to 1 month
Primary Bruising Average Bruise Change diagnose by cardiothoracic surgeon post operative- until release from hospitalization up to 1 month